Merimepodib (MMPD) in Triple Combination for the Treatment of Chronic Hepatitis C

This study has been completed.

Sponsor:

Information provided by:

Vertex Pharmaceuticals Incorporated

ClinicalTrials.gov Identifier:

NCT00088504

First received: July 27, 2004

Last updated: December 17, 2007

Last verified: December 2007

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2006
Estimated Primary Completion Date:	No date given

No publications provided by Vertex Pharmaceuticals Incorporated

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec;50(6):1719-26.

To Top